Programmed cell death-ligand 1 expression in hepatocellular carcinoma and its correlation with clinicopathological characteristics.
E-S grade
Hepatocellular carcinoma
Immunohistochemistry
PD-L1
TP53
Tumor mutational burden
Journal
Journal of gastroenterology and hepatology
ISSN: 1440-1746
Titre abrégé: J Gastroenterol Hepatol
Pays: Australia
ID NLM: 8607909
Informations de publication
Date de publication:
Sep 2021
Sep 2021
Historique:
revised:
23
01
2021
received:
09
07
2020
accepted:
22
02
2021
pubmed:
4
3
2021
medline:
18
3
2022
entrez:
3
3
2021
Statut:
ppublish
Résumé
Programmed cell death-ligand 1 (PD-L1) immunohistochemistry score has been approved as the predictive biomarker for anti-PD1/PD-L1 therapy in several advanced malignancies. Although its predictive role remained inconclusive in hepatocellular carcinoma, ongoing study of anti-PD1/PD-L1 therapy showed promising results. However, less is known about the PD-L1 immunohistochemistry score and factors correlated with it in hepatocellular carcinoma. We investigated PD-L1 immunohistochemistry scores in a large cohort of hepatocellular carcinoma, as well as its correlation with various clinical and genomic factors. Immunohistochemistry was performed to detect the expression of PD-L1 protein in 315 hepatocellular carcinoma tissues. All slides were independently reviewed by three senior pathologists. Next-generation YS panel (450 genes) sequencing was performed on 309 patients. Higher PD-L1 expression as measured by combined positive score (CPS) was associated with increased Edmondson-Steiner grade (grade III vs II, P = 0.041) and TP53 mutations (P = 0.021). PD-L1 CPS had no correlation with tumor mutational burden (Spearman's correlation coefficient 0.067). PD-L1 CPS was not significantly associated with hepatitis B virus infection. Our data indicated that patients with higher Edmondson-Steiner grade (grade III) had significantly higher PD-L1 CPS than patients with lower Edmondson-Steiner grade (grade II). Patients with TP53 mutations had significantly higher PD-L1 expression.
Sections du résumé
BACKGROUND AND AIM
OBJECTIVE
Programmed cell death-ligand 1 (PD-L1) immunohistochemistry score has been approved as the predictive biomarker for anti-PD1/PD-L1 therapy in several advanced malignancies. Although its predictive role remained inconclusive in hepatocellular carcinoma, ongoing study of anti-PD1/PD-L1 therapy showed promising results. However, less is known about the PD-L1 immunohistochemistry score and factors correlated with it in hepatocellular carcinoma. We investigated PD-L1 immunohistochemistry scores in a large cohort of hepatocellular carcinoma, as well as its correlation with various clinical and genomic factors.
METHODS
METHODS
Immunohistochemistry was performed to detect the expression of PD-L1 protein in 315 hepatocellular carcinoma tissues. All slides were independently reviewed by three senior pathologists. Next-generation YS panel (450 genes) sequencing was performed on 309 patients.
RESULTS
RESULTS
Higher PD-L1 expression as measured by combined positive score (CPS) was associated with increased Edmondson-Steiner grade (grade III vs II, P = 0.041) and TP53 mutations (P = 0.021). PD-L1 CPS had no correlation with tumor mutational burden (Spearman's correlation coefficient 0.067). PD-L1 CPS was not significantly associated with hepatitis B virus infection.
CONCLUSIONS
CONCLUSIONS
Our data indicated that patients with higher Edmondson-Steiner grade (grade III) had significantly higher PD-L1 CPS than patients with lower Edmondson-Steiner grade (grade II). Patients with TP53 mutations had significantly higher PD-L1 expression.
Identifiants
pubmed: 33656759
doi: 10.1111/jgh.15475
pmc: PMC8518358
doi:
Substances chimiques
B7-H1 Antigen
0
Biomarkers, Tumor
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
2601-2609Informations de copyright
© 2021 The Authors. Journal of Gastroenterology and Hepatology published by Journal of Gastroenterology and Hepatology Foundation and John Wiley & Sons Australia, Ltd.
Références
N Engl J Med. 2008 Jul 24;359(4):378-90
pubmed: 18650514
Lancet Oncol. 2019 Feb;20(2):282-296
pubmed: 30665869
Lancet. 2017 Jun 24;389(10088):2492-2502
pubmed: 28434648
J Hepatol. 2019 Sep;71(3):616-630
pubmed: 31195064
Genome Med. 2017 Apr 19;9(1):34
pubmed: 28420421
N Engl J Med. 2018 Jul 05;379(1):54-63
pubmed: 29972759
JCI Insight. 2019 Mar 21;4(6):
pubmed: 30895946
Lancet. 2018 Mar 24;391(10126):1163-1173
pubmed: 29433850
Mol Cancer Ther. 2015 Apr;14(4):847-56
pubmed: 25695955
Oncologist. 2019 Dec;24(12):e1294-e1302
pubmed: 31409745
Lancet. 2017 Jan 7;389(10064):56-66
pubmed: 27932229
J Immunol. 2007 May 15;178(10):6634-41
pubmed: 17475895
Pathol Res Pract. 2017 Jul;213(7):824-830
pubmed: 28554743
CA Cancer J Clin. 2018 Nov;68(6):394-424
pubmed: 30207593
Lancet. 2019 May 4;393(10183):1819-1830
pubmed: 30955977
Lancet. 2019 Apr 6;393(10179):1453-1464
pubmed: 30765123
Lancet Oncol. 2009 Jan;10(1):25-34
pubmed: 19095497
Lancet Oncol. 2018 Jul;19(7):940-952
pubmed: 29875066
Mod Pathol. 2019 Nov;32(11):1646-1656
pubmed: 31231126
Cancer. 2018 Jul 1;124(13):2785-2800
pubmed: 29786848
Br J Cancer. 2019 May;120(11):1033-1036
pubmed: 31061454
Lancet Respir Med. 2019 Apr;7(4):347-357
pubmed: 30876831
J Pathol. 2020 Jan;250(1):19-29
pubmed: 31471895
Eur J Gastroenterol Hepatol. 2019 Nov;31(11):1414-1423
pubmed: 31045613
J Gastroenterol Hepatol. 2021 Sep;36(9):2601-2609
pubmed: 33656759
Clin Cancer Res. 2019 Apr 1;25(7):2021-2023
pubmed: 30617138
Arch Pathol Lab Med. 2019 Mar;143(3):330-337
pubmed: 30028179
Ann Oncol. 2019 Apr 1;30(4):582-588
pubmed: 30715153
Nat Genet. 2019 Feb;51(2):202-206
pubmed: 30643254